Encorate Chrono300 mg

Encorate Chrono 300 mg is an anticonvulsant and mood-stabilising medicine used in the following conditions:

Established / Approved Uses

• Epilepsy: Monotherapy or adjunctive (add-on) therapy for complex partial seizures, simple and complex absence seizures, and as adjunctive therapy in patients with multiple seizure types that include absence seizures. Also widely used for generalized tonic-clonic, myoclonic and atonic seizures.
• Bipolar disorder: Treatment of acute manic or mixed episodes associated with bipolar disorder.
• Migraine prophylaxis: Prevention (not acute treatment) of migraine headaches in adults.

Other/Guideline-Supported Uses

• Febrile seizure prophylaxis and prevention of seizures following head injury or neurosurgery, used in some clinical settings under specialist supervision.
• Adjunct in status epilepticus (intravenous form), used in hospital settings when first-line agents are inadequate.

Use of Encorate Chrono 300 mg for indications outside of epilepsy, bipolar mania and migraine prophylaxis should be guided by a specialist physician.

Each formulation of Encorate Chrono 300 mg contains Encorate Chrono 300 mg as the active pharmaceutical ingredient. Encorate Chrono 300 mg is available in several dosage forms, including:

• Enteric-coated tablets (e.g. 200 mg)
• Controlled-release (prolonged-release) tablets (e.g. 200 mg, 300 mg, 500 mg)
• Oral syrup/liquid (e.g. 200 mg/5 mL)
• Injectable solution for intravenous use (e.g. 500 mg/5 mL), for use when oral therapy is not feasible

Excipients vary by manufacturer and formulation; refer to the specific product packaging for full excipient details.

Encorate Chrono 300 mg is a broad-spectrum anticonvulsant (antiepileptic) and mood-stabilising agent, chemically related to valproic acid. Encorate Chrono 300 mg is used in the long-term management of epilepsy, in the treatment of acute mania associated with bipolar disorder, and for prevention of migraine headaches.

Encorate Chrono 300 mg carries several serious, well-recognised safety concerns — including liver toxicity, pancreatitis, and major risk to a developing fetus during pregnancy — which is why it requires careful patient selection, monitoring, and physician supervision throughout treatment.

Encorate Chrono 300 mg belongs to the anticonvulsant (antiepileptic drug) class and is also classified as a mood stabiliser used in bipolar disorder, and as an antimigraine prophylactic agent.

The precise mechanism by which Encorate Chrono 300 mg exerts its therapeutic effects is not completely understood. Proposed mechanisms include:

• Increasing brain levels of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter, by inhibiting GABA transaminase and enhancing GABA synthesis.
• Blocking voltage-gated sodium channels, reducing sustained high-frequency repetitive neuronal firing.
• Modulating T-type calcium currents, thought to contribute to its efficacy against absence seizures.

Encorate Chrono 300 mg is well absorbed orally, is highly (~80-94%) bound to plasma proteins (binding is saturable and reduced in hepatic/renal disease and in the elderly), and is metabolised mainly in the liver via glucuronidation, mitochondrial beta-oxidation, and (to a lesser extent) cytochrome P450 pathways. It is excreted primarily in urine as glucuronide conjugates. Elimination half-life is roughly 9-16 hours in adults on monotherapy but varies considerably by age and hepatic function.

Encorate Chrono 300 mg enteric-coated and controlled-release tablets should be swallowed whole with water and should not be crushed or chewed, as this can affect drug release and increase gastrointestinal irritation. Encorate Chrono 300 mg may be taken with or after food to reduce stomach upset. The oral syrup should be measured using an appropriate dosing device.

The injectable form of Encorate Chrono 300 mg is intended for intravenous administration by a healthcare professional when oral therapy is temporarily not possible, and should be switched back to an equivalent oral dose as soon as feasible.

Encorate Chrono 300 mg has clinically significant interactions with a number of medicines, largely through effects on hepatic metabolism and protein binding:

• Other antiepileptics (phenytoin, carbamazepine, phenobarbital, lamotrigine): Encorate Chrono 300 mg can increase levels of lamotrigine, phenobarbital and free phenytoin (raising toxicity risk, including serious skin reactions with lamotrigine), while enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital) can lower valproate levels — dose adjustment and monitoring are often needed.
• Carbapenem antibiotics (e.g. meropenem, imipenem, ertapenem): Can markedly and rapidly reduce Encorate Chrono 300 mg plasma levels, risking loss of seizure control; concurrent use is generally avoided.
• Aspirin and highly protein-bound drugs: Can displace Encorate Chrono 300 mg from plasma proteins and inhibit its metabolism, increasing free drug levels and toxicity risk.
• Warfarin and other anticoagulants: Encorate Chrono 300 mg can increase the free fraction and effect of warfarin, raising bleeding risk — closer INR monitoring is advised.
• CNS depressants (benzodiazepines, opioids, alcohol): Additive sedation and CNS depression.
• Rifampin: Can increase clearance of Encorate Chrono 300 mg, lowering its plasma levels.
• Topiramate: Combination has been associated with hyperammonemia, sometimes with encephalopathy.

Always inform the prescribing physician of all other medicines being taken before starting Encorate Chrono 300 mg.

Side effects of Encorate Chrono 300 mg range from common and mild to rare but serious.

Common

• Nausea, vomiting, indigestion, abdominal pain, diarrhoea
• Drowsiness/somnolence, dizziness, tremor, headache
• Weight gain, increased appetite
• Hair thinning or hair loss (usually reversible)
• Menstrual irregularities

Less Common / Serious

• Elevated liver enzymes; rare but potentially fatal hepatotoxicity/liver failure (see Precautions and Warnings)
• Life-threatening pancreatitis (see Precautions and Warnings)
• Thrombocytopenia and platelet dysfunction, increasing bleeding risk
• Hyperammonemia, sometimes with encephalopathy (confusion, lethargy)
• Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) — rare
• Suicidal thoughts or behaviour (small increased risk seen across anticonvulsants as a class)

Patients should seek prompt medical attention for unusual bruising/bleeding, yellowing of skin or eyes, severe abdominal pain, unusual drowsiness/confusion, or any new mood or behaviour changes while taking Encorate Chrono 300 mg.

Pregnancy: Encorate Chrono 300 mg carries a major risk of birth defects, including neural tube defects (such as spina bifida), and has been associated with decreased IQ and neurodevelopmental problems in children exposed in utero. Encorate Chrono 300 mg is contraindicated in pregnancy when used for migraine prophylaxis. When used for epilepsy or bipolar disorder, Encorate Chrono 300 mg should be avoided in women who are pregnant or of childbearing potential unless alternative treatments are ineffective or not tolerated, and only if the potential benefit is judged to justify the potential risk to the fetus; use should follow specialist risk-management guidance, with folic acid supplementation considered, and always under close physician supervision. Women of childbearing potential should use effective contraception while on Encorate Chrono 300 mg unless planning pregnancy under specialist care. Do not stop Encorate Chrono 300 mg abruptly without medical advice, as uncontrolled seizures also pose serious risk to mother and fetus.

Lactation: Encorate Chrono 300 mg passes into breast milk in relatively small amounts. Many specialists consider breastfeeding compatible with maternal Encorate Chrono 300 mg use, but the decision should be individualised in consultation with a physician, with the infant monitored for possible drowsiness or feeding problems.

Boxed (Serious) Warnings

• Hepatotoxicity: Encorate Chrono 300 mg can cause fatal liver failure, particularly in children under two years of age (especially those on multiple anticonvulsants or with underlying metabolic/mitochondrial or seizure disorders). Liver function should be tested before starting Encorate Chrono 300 mg and monitored closely, especially during the first six months of therapy. Patients/caregivers should watch for loss of seizure control, malaise, weakness, lethargy, facial swelling, anorexia, vomiting, and jaundice.
• Pancreatitis: Life-threatening pancreatitis has occurred at any point during treatment with Encorate Chrono 300 mg, sometimes progressing rapidly. Patients should seek immediate medical attention for unexplained abdominal pain, nausea, vomiting, or anorexia, and Encorate Chrono 300 mg should generally be discontinued if pancreatitis is diagnosed.
• Fetal Risk (Teratogenicity): See Pregnancy and Lactation.

Other Important Precautions

• Do not stop abruptly: In epilepsy, Encorate Chrono 300 mg must be withdrawn gradually under medical supervision to avoid rebound/withdrawal seizures or status epilepticus.
• Thrombocytopenia/bleeding risk: Encorate Chrono 300 mg can reduce platelet count and impair platelet function. Platelet counts and coagulation studies should be checked before starting therapy and before any planned surgery.
• Hyperammonemia: Monitor for lethargy, vomiting, and altered mental status, particularly in patients with unexplained lethargy or vomiting, or with urea cycle disorder risk factors.
• Suicidal behaviour/mood changes: Antiepileptic drugs, including Encorate Chrono 300 mg, are associated with a small increased risk of suicidal thoughts or behaviour; monitor for depression, unusual mood or behaviour change.
• Use with caution in patients with systemic lupus erythematosus, prior liver disease in the family, or known mitochondrial disease.
• May cause drowsiness or dizziness — caution when driving or operating machinery.

Overdose of Encorate Chrono 300 mg is a medical emergency. Symptoms can include deep sedation, coma, muscle weakness, low blood pressure, heart rhythm/conduction disturbances, and, in severe cases, death. If overdose of Encorate Chrono 300 mg is suspected, seek immediate medical attention or contact emergency services/a poison control centre right away. Do not attempt to treat an overdose at home. Hospital management is supportive and may include gastric decontamination if appropriate and, in severe cases, hemodialysis.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric patients: See Pediatric Uses — children under two years carry the highest risk of fatal hepatotoxicity with Encorate Chrono 300 mg, especially on multiple anticonvulsants or with metabolic disorders.
• Elderly patients: Clearance of Encorate Chrono 300 mg is reduced and free drug levels increased in the elderly; lower starting doses and slower titration are recommended, with monitoring for excess sedation, reduced food/fluid intake, and dehydration.
• Hepatic impairment: Encorate Chrono 300 mg is contraindicated in significant hepatic disease/dysfunction — see Contraindications.
• Renal impairment: No routine dose adjustment is required based on renal function alone, but closer monitoring is advised since the unbound (active) fraction of drug increases; dose may need to be lowered in significant renal impairment.
• Pregnancy and women of childbearing potential: See Pregnancy and Lactation.

Duration of treatment with Encorate Chrono 300 mg is individualised by the treating physician based on the condition being treated. In epilepsy, treatment is typically long-term/chronic, often continued for years, with periodic reassessment of continued need. In acute mania, treatment continues through the acute episode with ongoing reassessment for maintenance therapy. For migraine prophylaxis, response is usually assessed after several weeks to months, with periodic review of continued need. Encorate Chrono 300 mg should never be stopped abruptly without medical advice.

Encorate Chrono 300 mg is classified under: Anticonvulsants / Antiepileptic drugs; Mood stabilisers (used in bipolar disorder); Antimigraine prophylactic agents.

Encorate Chrono 300 mg is thought to increase concentrations of the inhibitory neurotransmitter GABA in the brain, block voltage-gated sodium channels to reduce repetitive neuronal firing, and modulate T-type calcium channels — together raising the seizure threshold and stabilising abnormal neuronal excitability. The exact mechanism underlying its antimanic and antimigraine effects is less well defined but is believed to relate to these same GABAergic and neuronal-excitability effects.

D

Encorate Chrono 300 mg is used in children for epilepsy, with dosing individualised by weight and age under specialist supervision. Use in bipolar mania has not been systematically studied in patients under 18 years, and use for migraine prophylaxis has not been established in children.

Important safety note: Children under two years of age are at considerably increased risk of fatal hepatotoxicity with Encorate Chrono 300 mg, particularly when receiving multiple anticonvulsants, or with congenital metabolic disorders, severe seizure disorders with mental retardation, or organic brain disease. Encorate Chrono 300 mg should be used with extreme caution as monotherapy in this age group, and only when the anticipated benefits clearly outweigh the risks. Testing for underlying mitochondrial disorders (e.g. POLG mutations) should be considered before use in children with suggestive clinical features, as Encorate Chrono 300 mg is contraindicated in known POLG-related disorders in children under two. Safety and efficacy for indications other than epilepsy are not established in the pediatric population.